跳至主要内容
临床试验/NCT06635694
NCT06635694进行中(未招募)不适用

naVIGation Invitations Liver surveillANce upTake

Imperial College London1 个研究点 分布在 1 个国家目标入组 652 人开始时间: 2025年2月27日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
652
试验地点
1
主要终点
Proportion of patients in each arm attending HCC surveillance regularly

研究概览

简要总结

This study aims to evaluate the efficacy of Patient Navigators and mailed surveillance invitations on attendance of Hepatocellular Carcinoma (HCC) ultrasound surveillance appointments. The investigators hypothesise that mailed invitations and Patient Navigators will improve attendance at HCC surveillance appointments and increase the proportion of patients diagnosed at an early stage, compared with a control group receiving usual care.

详细描述

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Despite advances in treatment options, prognosis remains worrying, with 5-year survival rates remaining less than 20%.

Surveillance for HCC involves six-monthly ultrasounds (US) of the liver and has been demonstrated to increase rate of early diagnosis, which translates to improved survival. However, the uptake of HCC surveillance is low internationally; in Western countries, only 20% of patients eligible for HCC surveillance receive a surveillance test.

The current provision of HCC surveillance in the UK is ad hoc: eligible patients have six-monthly ultrasound requested by their clinician (usually a gastroenterologist, hepatologist or hepatology clinical nurse specialist). Patients receive an ultrasound appointment in the post with no formal invitation or information about the surveillance test. Work with focus groups suggests lack of knowledge and fear are barriers to HCC surveillance attendance.

Previous research has shown that patient navigation increased HCC surveillance uptake in an American population. However, there has been no research on interventions aimed at improving surveillance uptake in the UK population.

The study predicts that the mailed invitations and Patient Navigators will improve patient attendance at HCC surveillance and increases the number of patients diagnosed with early-stage HCC, compared with usual care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 years of age or older
  • •ECOG performance status of 0-2
  • •Eligible for HCC surveillance as defined by NICE and EASL criteria
  • •Child Pugh A or B cirrhosis
  • •Child Pugh C cirrhosis AND on liver transplant waiting list
  • •High risk chronic hepatitis B

排除标准

  • •Previous or current diagnosis of HCC
  • •Child Pugh C cirrhosis
  • •Frailty (Clinical Frailty Scale >7)
  • •Previous liver transplant

研究组 & 干预措施

Usual Care

Responsible clinician will request surveillance imaging and ultrasound appointment will be booked using an automated call/recall system. A formal invitation to surveillance and an informational sheet will be sent by post to patient's home address, addressing concerns including fear, and FAQs e.g. duration of scan and level of discomfort. Patients will receive a reminder 2 weeks prior to their appointment. Results will be automatically sent to the relevant hepatology unit and GP. Patients will be informed of results by mail or through "patientknowsbest" app, and invited for repeat ultrasound in 6 months. Patients with abnormal results will be contacted by the direct care team to organise further investigations. Non-attendance will be followed by a further appointment letter/text. Patients who fail to attend 2 appointments will be contacted by the direct care team. Their reasons for non-attendance will be recorded and GP contacted.

Patient Navigator

Patients will receive usual care plus a scripted phone call from a Patient Navigator the week prior to the surveillance appointment to remind patients, offer to reschedule the appointment if the patient is unable to attend, and address any concerns about the appointment. All other procedures will be the same as usual care. Additionally, Navigators will call patients who have not attended surveillance imaging appointments to explore any barriers to attendance and how these might be addressed.

结局指标

主要结局

Proportion of patients in each arm attending HCC surveillance regularly

时间窗: 2 years

Attendance rates at 6-months intervals

时间窗: 2 years

次要结局

  • Proportion of patients in each arm diagnosed with HCC compared with late-stage HCC(2 years)
  • Cost of intervention compared to standard of care(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Increasing Colorectal Cancer Screening Uptake With a Patient NavigatorColorectal Cancer
NCT01506687Cancer Care Ontario750
已完成
不适用
Redes II National Patient Navigator Intervention StudyBreast Cancer
NCT02269033The University of Texas Health Science Center at San Antonio480
已完成
不适用
Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 PandemicBreast Cancer
NCT05181722Johns Hopkins University126
已完成
不适用
Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary CareMinority Smokers
NCT01678118Memorial Sloan Kettering Cancer Center16
已完成
不适用
Patient Portal and Navigation Program in Providing Information for Asian American Cancer PatientsStage I Colorectal Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Liver CancerCaregiverStage II Colorectal Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Malignant NeoplasmPhysicianStage I Liver CancerStage IA3 Lung Cancer AJCC v8Stage II Liver CancerStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Colorectal Cancer AJCC v8Stage IIC Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8
NCT03867916University of California, San Francisco106